학술논문
A DOUBLE BLIND COMPARATIVE STUDY ON THE EFFICACY OF S6472, CEFACLOR AND AMOXICILLIN, IN THE TREATMENT OF BACTERIAL PNEUMONIA / 細菌性肺炎に対するS6472, CefaclorとAmoxicillinの二重盲検法による臨床評価の比較
Document Type
Journal Article
Author
AKIO EBINA; AKIO HIRAYAMA; AKIRA SAITOH; AKIRA SUZUKI; AKIRA UJIIE; AKIRA WATANABE; CHOEI ITOH; EINOSUKE ODAGAKI; FUMIEI KONDO; FUMIO NAGAHAMA; FUMITOSHI YAMAUCHI; HAJIME WATANABE; HIDETAKA SATOH; HIDETOSHI SHIBAKI; HIROMI YAOI; HIROSHI ISHIKAWA; HIROSHI KURAMITSU; HIROSHI TAKAGI; HIROYUKI NAKAI; HIROYUKI TOKUNAKA; HITOSHI YASHIRO; IZUMI HAYASHI; JUTARO SHIMOMURA; KATSUHIRO OKAMOTO; KATSUO SUZUKI; KATSUYOSHI MORIYA; KAZUO SATOH; KAZUO TAKEBE; KAZUTOSHI GOMI; KEISUKE TAKEUCHI; KENKICHI SHIKANAI; KIICHI KAISHIO; KIYOFUMI ISHIKAWA; KIYOSHI KAWAMORITA; KIYOSHI KONNO; KIYOSHI OMURO; KOHKI KIKUCHI; KOHSAKU NAGAI; KOHTARO OIZUMI; KOHZO KURAHASHI; KOTARO ITAKURA; KYUICHIRO SEKINE; MASAAKI ITASAWA; MASAHIDE SHINOHARA; MASAHIKO YAMAGISHI; MASAO SATOH; MASASHI TAMURA; MASASHI YONEDA; MASUMI TOMISAWA; MATSUMI TOSAKA; MIKIHIKO TANGO; MIKIO MATSUI; MIKIYA SATOH; MITSUO NAKAMURA; MORIKUNI ABE; NAOYOSHI MASAKI; NOBORU ASABU; NOBUHIRO SASAKI; NOBUHISA SATOH; NORIHIKO HIROTA; NORIMI KOMETANI; OSAMU YAJIMA; SABURO SHINDOH; SEIICHI AONUMA; SHIGEKI MORI; SHIGEMI KOHSAKA; SHIGEO TAKISAWA; SHINICHI OSHIMA; SOICHIRO UEHARA; SOKICHI ONODERA; SYUICHIRO YOSHIDA; SYUJI CHIBA; TADASHI MIYASAWA; TADASHI MURAKAMI; TAKASHI ITOH; TAKASHI TAKAHORI; TAKASHI TSURUYA; TAKEHISA CHIMOTO; TATSURO IRIE; TATSUYA ISHIZUKA; TERUO HASUIKE; TETSUO SHIMIZU; TOHRU NATSUISAKA; TOMOKO YAMAMOTO; TOORU NAKABAYASHI; TOYOICHI TAMURA; TSUGUSHI ITO; TSUKASA YOSHIDA; TSUYOSHI KIKUIRI; YASUYUKI SUZUKI; YOICHI GOCHO; YOMEI HIRAGA; YOSHIAKI ICHISHIMA; YOSHIHIRO KUMASAKA; YOSHIKATSU NEMOTO; YOSHIO KURIHARA; YOSHIRO ISHII; YUICHI HIRAI; YUJI IKEDA; YUZURU MATSUMOTO; 一島 嘉明; 上原 総一郎; 下村 寿太郎; 中井 祐之; 中村 光男; 中林 透; 丹呉 幹彦; 五味 和俊; 今野 淳; 伊藤 亜司; 伊藤 長英; 伊藤 隆司; 佐々木 信博; 佐藤 信久; 佐藤 和男; 佐藤 幹弥; 佐藤 正男; 佐藤 秀隆; 倉光 宏; 倉橋 幸造; 入江 達朗; 八代 均; 千葉 修二; 吉田 司; 吉田 秀一郎; 夏井坂 徹; 大島 信一; 大泉 耕太郎; 守屋 克良; 宮沢 正; 富沢 磨須美; 小室 淳; 小田柿 栄之輔; 小野寺 壮吉; 山内 文俊; 山岸 雅彦; 山本 朝子; 岡本 勝博; 川守田 淳; 平井 裕一; 平山 亮夫; 平賀 洋明; 広田 則彦; 後町 洋一; 徳中 弘之; 斎藤 玲; 新藤 三郎; 村上 匡; 松井 美紀夫; 松本 ゆづる; 板倉 康太郎; 板澤 正明; 林 泉; 柾木 尚義; 栗原 義夫; 根本 義勝; 森 茂樹; 武内 恵輔; 武部 和夫; 氏家 昭; 池田 裕次; 海塩 毅一; 清水 哲雄; 渡辺 一; 渡辺 彰; 滝沢 茂夫; 熊坂 義裕; 田村 昌士; 田村 豊一; 登坂 松三; 矢嶋 勇; 矢追 博美; 知本 武久; 石井 禎郎; 石塚 竜哉; 石川 浩; 石川 清文; 篠原 正英; 米田 政志; 米谷 則美; 芝木 秀俊; 菊入 剛; 菊地 弘毅; 蓮池 照夫; 蝦名 昭男; 近藤 文衛; 鈴木 克男; 鈴木 康之; 鈴木 明; 長井 弘策; 長浜 文雄; 関根 球一郎; 阿部 守邦; 青沼 清一; 香坂 茂美; 高堀 昂; 高木 浩; 鶴谷 隆司; 鹿内 健吉; 麻生 昇
Source
The Japanese Journal of Antibiotics. 1986, 39(3):853
Subject
Language
Japanese
ISSN
0368-2781
2186-5477
2186-5477
Abstract
The S6472 is a 4: 6 mixture of 2 types of granules of cefaclor (CCL) coated with different films; one type of granules is soluble at low pH's and absorbed in the stomach while the other type is soluble at high pH's and absorbed in the intestine. The difference in absorption sites makes it possible to maintain blood concentrations of the drug at clinically efficient levels for a longer period of time compared with ordinary CCL.The efficacy, safety and usefulness of S6472 in the treatment of bacterial pneumonia was compared with those of ordinary CCL and of amoxicillin (AMPC) by the blind method.The patients entered in this trial were those who had bacterial pneumonia or lung abscess and were 16 years or above of age.The S6472 was given orally for 14 days at a daily dose of 1,500mg (750mg each after breakfast and supper), CCL was given at a daily dose of 1,500mg (500mg each after every meal), and AMPC at 2,000mg (500mg each after every meal and at the bedtime). To make the study blind, placeboes were matched with the test drug so that patients in every treatment group took 4 doses per day.Out of a total of 195 patients thus treated, 179 patients (55 in S6472 group, 62 in CCL group and 62 in AMPC group) were adopted for the evaluation by committee members while 185 patients (58 in S6472 group, 63 in CCL group and 64 in AMPC group) by controllers.When clinical results of the 3 treatment groups were compared, no statistically significant differences were observed in efficacy rates (cure rates), incidences of side effects nor abnormal findings of laboratory tests.From these results of this trial, it is concluded that oral administration of 750mg of S6472 twice a day (1,500mg per day) is as effective and useful as that of 500mg of ordinary CCL 3 times a day (1,500mg per day) or 500mg of AMPC 4 times a day (2,000mg per day) in the treatment of bacterial pneumonia or lung abscess.